Montgomery, KA (Jun 2008). "Sexual Desire Disorders". Psychiatry (Edgmont). 5 (6): 50–55. PMC 2695750. PMID 19727285. Basson, R; Leiblum, S; Brotto, L;  et al. (December 2003). "Definitions of womens sexual dysfunction reconsidered: advocating expansion and revision". Journal of Psychosomatic Obstetrics and Gynaecology. 24 (4): 221–9. doi:10.3109/01674820309074686. PMID 14702882. S2CID 4780569. Warnock, JJ (2002). "Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment". CNS Drugs. 16 (11): 745–53. doi:10.2165/00023210-200216110-00003. PMID 12383030. S2CID 24669452. Basson, R (10 May 2005). "Womens sexual dysfunction: revised and expanded definitions". Canadian Medical Association Journal. Canadian Medical Association. 172 (10): 1327–1333. doi:10.1503/cmaj.1020174. PMC 557105. PMID 15883409. Nappi, RE; Wawra, K; Schmitt, S (Jun 2006). "Hypoactive sexual desire disorder in postmenopausal women". Gynecological Endocrinology. 22 (6): 318–23. doi:10.1080/09513590600762265. PMID 16785156. S2CID 24526712. == External links ==
Society and culture
Legal status
In November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Voraxaze, intended to reduce toxic plasma methotrexate concentration. The applicant for this medicinal product is SERB SAS. Glucarpidase was approved for medical use in the European Union in January 2022. References
External links
"Glucarpidase". Drug Information Portal. U.S. National Library of Medicine.